Abstract 2522: Identification and characterization of new highly selective and potent BRAF inhibitors
Maurizio Pulici(Nerviano Medical Sciences), Marina Ciomei(Nerviano Medical Sciences), Francesco Colotta(Humanitas University), Daniele Donati(Nerviano Medical Sciences), Sonia Biondaro(Nerviano Medical Sciences), Rosita Lupi(Nerviano Medical Sciences), Wilma Pastori(Nerviano Medical Sciences), Fabio Zuccotto, Elena Casale, Eduard Felder, Gabriella Traquandi(Nerviano Medical Sciences), Fabio Gasparri(Nerviano Medical Sciences), Antonella Leone(CoNISMa), Enrico Pesenti, Francesco Caprera(Nerviano Medical Sciences), Chiara Marchionni(Nerviano Medical Sciences), Michele Modugno(Nerviano Medical Sciences), Nadia Amboldi(University of Pavia), Arturo Galvani(Nerviano Medical Sciences), Antonella Isacchi(Nerviano Medical Sciences)
Cited by 0
Related Papers
Discovery of drug mode of action and drug repositioning from transcriptional responses
|Proceedings of the National Academy of Sciences|2010|853
Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: Prevention of reperfusion injury
|Proceedings of the National Academy of Sciences|2004|339
Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
|Molecular Cancer Therapeutics|2016|317
Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis.
|Proceedings of the National Academy of Sciences|1995|205